Drug Discovery World

DECEMBER 1, 2022

Based on Nakhoda and Olszanski, 2022 (Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies), lack of an optimal biomarker is one of the main challenges to clinical trial success. Director, Application Development, LevitasBio will present the event. Camila Egidio. Register here.

RNA 130

RNA Clinical Trials Drugs Trials 130

Drug Discovery World

JUNE 21, 2023

Citius Pharmaceuticals has revealed positive results from its Phase IIb Study of Halo-Lido (CITI-002) for the treatment of haemorrhoids. Moreover, there were no reported significant adverse events and CITI-002 was well tolerated by patients in the study.

Trials 130

Trials Treatment Clinical Trials Clinical Development 130

Drug Discovery World

SEPTEMBER 16, 2024

The authors found that T cell malignancies represented a small minority of adverse events at just 1.5%. The European Medicines Agency (EMA) has also reduced daily hospital safety monitoring for patients following treatment with CAR-T cell therapies Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel).

Therapies 147

Therapies Clinical Trials Hospitals Treatment 147

Drug Discovery World

JANUARY 30, 2023

The event will cover aspects affecting growth of the CGT market, including how manufacturing technologies are enabling drug development, what these therapies mean for the healthcare market, and the opportunities for developers. The post Webinar: Transforming disease treatment with CGT appeared first on Drug Discovery World (DDW).

Disease 130

Disease Treatment Therapies Drug Development 130

Drug Discovery World

DECEMBER 23, 2022

A study by Ellipses Pharma, a global drug development company focused on accelerating the development of new oncology treatments, has presented preliminary data from the first in human Phase I/II trial of EP0042, a dual FLT-3 an Aurora kinase inhibitor, in patients with acute myeloid leukaemia (AML). . The data . Official comments .

Treatment 130

Treatment Clinical Trials Drug Development Trials 130

Drug Discovery World

APRIL 16, 2023

Patients with treatment-naïve resectable non-small cell lung cancer (NSCLC) who received neoadjuvant durvalumab (Imfinzi) plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival (EFS) and pathological complete response (pCR) compared with those who received neoadjuvant chemotherapy alone. Overall, 77.6%

Treatment 130

Treatment Therapies Clinical Trials Trials 130

Drug Discovery World

FEBRUARY 9, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to AstraZeneca for Imfinzi (durvalumab) in combination with gemcitabine and cisplatin in Great Britain for use as a first-line treatment of adults with locally advanced, unresectable or metastatic biliary tract cancer (BTC). versus 11.5%).

Treatment 130

Treatment Clinical Research International FDA 130

SCIENMAG: Medicine & Health

JUNE 24, 2023

About The Study: The findings of this study suggest that treatment with bempedoic acid in high-risk primary prevention patients unable to tolerate recommended doses of statins has the potential to reduce major adverse cardiovascular events. Authors: Steven E. Nissen, M.D., of the Cleveland Clinic, is the corresponding author.

Treatment 68

Treatment 68

Drug Discovery World

SEPTEMBER 13, 2024

QL Biopharm, a clinical stage biopharmaceutical company developing biologic drugs for the treatment of metabolic diseases, has shared Phase Ic clinical data for its lead drug candidate ZT002. The majority of adverse events (AEs) were mild or moderate in severity, no serious AEs were reported in the ZT002 treatment groups.

Pharmacokinetics 147

Pharmacokinetics Drugs Treatment FDA 147

Drug Discovery World

MAY 10, 2024

291 patients were randomised to treatment either with evenamide or placebo as add-on to their current antipsychotic therapy. There was no difference in the incidence of CNS, psychiatric, gastrointestinal or other adverse events between evenamide and placebo. points, compared to 7.6

International 182

International Pharmaceuticals Treatment Trials 182

Chemical Biology and Drug Design

FEBRUARY 13, 2024

Some researchers proposed that the symptoms involved in AD (loss of memory, cognitive impairment, and amnesia) are the main event linked to the cholinergic neurotransmitter (acetylcholine). This review focuses on the last 10 year's literature search on huprine and its analogues for the treatment of AD.

Disease 100

Disease Treatment Therapies Research 100

Broad Institute

JULY 11, 2024

Targeted drug treatment leads tumor cells to imitate viral infection By Ari Navetta July 11, 2024 Breadcrumb Home Targeted drug treatment leads tumor cells to imitate viral infection Exploiting "viral mimicry," mIDH1 inhibitors trick tumors into thinking they are infected with a virus.

Treatment 72

Treatment Immune Response Virus Drugs 72

Drug Discovery World

OCTOBER 1, 2024

In this free online event at 3pm BST on 24 October, hosted by DDW and co-sponsored by ApconiX and AxoSim, leading industry figures will outline the areas of opportunity and challenges in the neuroscience drug discovery & development sector. What you will learn: Where is the opportunity in the neuroscience market?

Science 130

Science Therapies Marketing Production 130

Drug Discovery World

JUNE 12, 2024

Immune-checkpoint inhibitor (ICI) therapy has transformed treatment outcomes for RCC. However, ICIs can also trigger immune-related adverse events and may not benefit all patients. If successful, the data we generate could help us learn more about the biology of renal cell carcinoma and its treatments.”

Protein Expression 130

Protein Expression Medical Schools Treatment Therapies 130

Drug Discovery World

MAY 8, 2024

“No medication has been approved by the FDA for vaping cessation in the United States,” said lead author Nancy Rigotti, Director of Massachusetts General Hospital’s Tobacco Research and Treatment Center and a Professor of Medicine at Harvard Medical School. For cytisinicline treatment compared to placebo, 31.8% versus 15.1%

Clinical Trials 182

Clinical Trials Compliance Trials Drugs 182

Drug Discovery World

NOVEMBER 30, 2023

The reports were received from clinical trials and postmarketing adverse event (AE) data sources. The FDA has cautioned that patients and clinical trial participants receiving treatment with these products should be monitored life-long for new malignancies.

FDA 162

FDA Clinical Trials Therapies Production 162

Drug Discovery World

APRIL 18, 2024

First results from the EAGLE-1 Phase III trial for gepotidacin show that two oral doses of the antibiotic displayed superior success rates (92.6%) when compared to the combination treatment of ceftriaxone and oral azithromycin, which saw a 91.2% The imperative for innovative treatments has never been clearer. success rate.

Trials 130

Trials DNA Treatment Regulations 130

PLOS: DNA Science

MARCH 28, 2024

FDA classifies it as a “nonsteroidal treatment” – not a gene therapy, but it affects gene expression. A gene-based treatment would have to alter many cells to exert a noticeable effect. In 2023, two gene-based treatments became available. Muscle makes up about 40 percent of body weight. million DNA bases.

FDA Approval 87

FDA Approval Treatment FDA DNA 87

Drug Discovery World

JANUARY 29, 2024

Leading experts in genomics, personalised medicine and drug discovery convened at the Precision Medicine Community Event in London to unveil the latest advancements shaping the future of healthcare.

Clinical Trials 147

Clinical Trials Pharmaceutical Companies Trials Pharmaceuticals 147

Drug Discovery World

SEPTEMBER 2, 2024

In all three arms, the treatment regimens were observed to have a favourable safety profile and to be generally well tolerated, with only 12 of the 175 patients (four patients in each arm) discontinuing treatment due to adverse events.

Trials 147

Trials Treatment Clinical Trials Drugs 147

Drug Discovery World

AUGUST 23, 2024

A new study indicates that anti-obesity drug semaglutide helps prevent cardiac events among overweight people who have cardiovascular disease, even if they also have heart failure. Semaglutide is the active ingredient in Wegovy and Ozempic. Read the full paper in The Lancet.

Disease 147

Disease Trials Clinical Trials Regulations 147

Drug Discovery World

JUNE 28, 2023

Takeda has revealed favourable interim results from its Phase III crossover trial evaluating the safety and efficacy of TAK-755 (recombinant ADAMTS13) replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura (cTTP). Acute TTP events have a mortality rate of >90%, if left untreated.

Trials 130

Trials Clinical Trials Drugs Therapies 130

Drug Discovery World

FEBRUARY 21, 2024

RA: What are the clinical benefits of using the patient’s own cells as a treatment? PS : Because we are using the patient’s own NK cells without any genetic modification, there are no drug-related adverse events, and patients can be treated indefinitely without any pre-treatment or lymphodepletion.

Therapies 306

Therapies Trials Treatment Disease 306

Drug Discovery World

JUNE 21, 2024

Allogene Therapeutics and Foresight Diagnostics have announced the initiation of a Phase II trial evaluating the use of cemacabtagene ansegedleucel (cema-cel) as part of the first line treatment regimen for newly diagnosed large B-cell lymphoma (LBCL) patients who are likely to relapse.

Trials 147

Trials Compliance Clinical Trials Doctors 147

Drug Discovery World

AUGUST 2, 2023

Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. and three-year event-free (EFS) of 73.7%. and three-year event-free (EFS) of 73.7%.

Licensing 246

Licensing Licensing Hospitals Therapies 246

Drug Discovery World

AUGUST 2, 2024

GLP-1 receptor agonists have dominated the headlines this week, with data revealed on new potential beneficial effects of treatment with semaglutide and dual receptor agonists like pemvidutide. of subjects achieving LFC normalisation after 12 weeks of treatment. relative reduction in liver fat content (LFC), with up to 55.6%

Clinical Trials 130

Clinical Trials Drugs Treatment Disease 130

Drug Discovery World

SEPTEMBER 26, 2023

Although viruses mutate all the time, the researchers identified mutational events in the global sequencing database which looked very different to typical patterns of Covid-19 mutations, and that they were strongly associated with individuals who had taken molnupiravir.

Virus 130

Virus Clinical Trials Treatment Research 130

Drug Discovery World

AUGUST 2, 2024

This translates to a placebo-adjusted weight loss from baseline of 7.4%, 9.2%, 11.3%, and 13.10% in the treatment groups. In a Phase I trial of an oral tablet formulation of VK2735, up to 3.3% placebo-adjusted mean weight loss (5.3% from baseline) was observed after 28 days.

Clinical Trials 147

Clinical Trials Drugs Trials Treatment 147

Drug Discovery World

DECEMBER 12, 2023

Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a Phase Ib/IIa study. During the trial, EXN407 met all safety and pharmacokinetic parameters and displayed encouraging signals of biological activity.

Small Molecule 130

Small Molecule Trials Pharmacokinetics Treatment 130

Drug Discovery World

JANUARY 23, 2023

Over the three days of Advanced Therapies Week (ATW) 2023 in Miami, Florida, US, from 18 to 20 January, DDW’s Megan Thomas heard from attendees about what they were most looking forward to learning from the event, as well as why they think the potential of cell and gene therapies outweighs the obstacles that must be overcome to achieve it.

Therapies 246

Therapies Small Molecule Production Treatment 246

Drug Discovery World

APRIL 11, 2024

COPD currently has limited treatment options despite being a leading cause of death globally. However, in contrast to antibiotic macrolides, GI adverse events were comparable between the EP395 and placebo-treated participants, and no adverse events related to hearing were reported.

Therapies 130

Therapies Clinical Trials Disease Trials 130

Drug Discovery World

JUNE 23, 2023

PTC518 treatment was also demonstrated to be well tolerated, with no treatment-related serious adverse events, no reports of peripheral neuropathy or dose-limiting toxicities. In addition, PTC518 exposure in the cerebrospinal fluid (CSF) was consistent with or higher than plasma unbound drug levels.

Disease 130

Disease Trials Treatment Drugs 130

Drug Discovery World

SEPTEMBER 6, 2024

Ongoing evaluation of the study has revealed no serious adverse events related to the administration of AGuIX, highlighting the favourable safety profile of this drug candidate.

Trials 130

Trials Clinical Trials Clinical Development Hospitals 130

The Pharma Data

MARCH 2, 2021

BLINCYTO demonstrated significantly prolonged event-free survival (events were defined by relapse, death, second malignancy, or failure to achieve complete remission) compared with chemotherapy. months follow-up, 69% of patients treated with BLINCYTO were alive and event-free compared with 43% of patients treated with chemotherapy.

Treatment 52

Treatment Trials Therapies Hospitals 52

Drug Discovery World

JULY 13, 2023

A new adverse event Liraglutide and semaglutide are widely used, with an exposure of over 20 million patient-years to date. A signal is information on a new adverse event that is potentially caused by a medicine or a new aspect of a known adverse event that warrants further investigation.

Drugs 130

Drugs Production Treatment 130

Drug Discovery World

JUNE 28, 2024

A new Phase II trial, REGENERATE-PD, will study AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy for the treatment of moderate-stage Parkinson’s disease. The trial will include an estimated 87 subjects with study sites located in the US, UK and Europe.

Therapies 147

Therapies Disease Medical Schools Trials 147

Drug Discovery World

AUGUST 30, 2022

The conference is the European twin to Phacilitate Advanced Therapies Week, an event held in January in Florida, US. The event is tailored to a European audience looking to commercialise ATMPs globally, as well as a global audience looking to understand and expand into the European market.

Therapies 246

Therapies Hospitals Clinical Trials Clinical Development 246